|
Australia Biotech Invest 2013( Oct 28-29, Melbourne): Connecting Capital with Innovation
hits:3888 Date:09/12/13
Australia Biotech Invest 2013
28-29 October 2013
Melbourne Convention and Exhibition Centre,Victoria ,Australia
Benefit from expert analysis on the evolving landscape of biotech investment from:
Join Australia Biotech Invest 2013 to:
• Get up-to date on the latest trends and opportunities in global biotech investment
• Hear 30+ public and private biotech companies present their pipeline and investment case
• Discuss partnering, investment and capital raising strategies with our expert panels
• Gain insight into IP protection issues and find out how best to safeguard your IP rights
• Learn about Australia鈥檚 biotech R&D tax incentives and how to benefit from them
• Identify exciting new business opportunities at the on-site exhibition
• Network with biotech CEOs, international investors, big pharma, brokers and industry analysts
• Access our online partnering system to set up 1-to-1 meetings and make more deals!
Australia鈥檚 premier biotech investment event
To be held in Melbourne, one of the great life science hubs in the world, Australia Biotech Invest will be Australia鈥檚 biggest biotech investment event to date. Building on AusBiotech鈥檚 successful Australasian Life Science Investment Summits, Australia Biotech Invest extends to a two-day programme and will gather together hundreds of life science investors from Australia and across the globe to discuss investment and partnership opportunities with a line-up of cutting-edge biotech companies.
Combining high-value content with concrete investment opportunities
In addition to biotech company presentations, the programme of Australia Biotech Invest 2013 features a mix of expert keynotes, investor and analyst panels and focus sessions to provide you with valuable market intelligence and act as your guide to biotech investment.
Strong performance for the biotech sector
This year is shaping up to be a good year for investment in the biotech sector. Globally, biotech stocks are surging, in the United States IPOs are being launched at the highest rate in more than 10 years and overall strong performance of the sector has placed biotech back in the investor limelight. With a positive long-term outlook, now is an excellent time to learn more about how to gain exposure to this exciting sector.
| Sponsorship and Exhibiting Opportunities: |
Who Should Attend? |
Biotech companies come and present your pipeline to the assembled audience of investors and big pharma representatives and raise funds or set up partnerships to drive your research forward.
Benefits for presenting biotech companies:
- Gain access to senior professionals representing investable capital globally
- Pitch your investment case in an 8-minute spotlight presentation on the main conference stage to the assembled audience
- Enjoy exposure on the targeted marketing campaign reaching out to our extensive investor database and to key business development professionals in pharma and big biotech
- Explain further details of your research at your dedicated table top space at the exhibition
- Set up one-to-one meetings to discuss deals in private
- Meet with all the key stakeholders under one roof and enjoy excellent networking opportunities throughout the conference
|
- Institutional investors
- Private equity investors
- Venture capitalists
- Angel investors
- Family offices
- Fund managers
- Major pharmaceutical companies
- Investment banks
- Brokerage firms
- Stock exchanges
- Consultants
- Analysts
- Law firms
- CMOs and CROs Plus: Biotech companies looking for funding or partners
|
Biotech companies confirmed to present so far include:
| For enquiries, please contact: |
|
Australia / New Zealand
Speaking & Sponsorship enquiries
Hayley Laing
T: +613 9828 1400
E:hlaing@ausbiotech.org |
Asia / Rest of the World
Speaking enquiries
Lot de Jongh
T: +852 2531 6140
E:lot.jongh@beaconevents.com
|
Asia / Rest of the World
Sponsorship enquiries
King Tai
T: +852 2531 6125
E:king.tai@beaconevents.com |
Conference Day One 28 October 2013
| 08:30 |
Registration and morning coffee |
| 09:00 |
WELCOME & OFFICIAL OPENING The Honourable Gordon Rich-Phillips MLC, Minister for Technology, STATE GOVERNMENT OF VICTORIA Glenn Cross, Chief Operating Officer, AUSBIOTECH |
| 09:10 |
Conference chairman鈥檚 opening remarks and business card exchange David Blake, Editor, BIOSHARES |
|
GLOBAL STATE OF BIOTECH INVESTMENT
|
| 09:15 |
Global biotech investment trends and opportunities
• Analysing investment and business trends driving biotechnology today
• Demographic,macro-economic and policy development simpacting the sector
• Exploring innovative investment strategies to benefit from emerging opportunities inbiotech
Dr Eric Shiozaki,Director,APPOSITE |
| 09:35 |
Exploring biotech鈥檚 evolving investment landscape 鈥 challenges and opportunities
- Long-term investment outlook for biotech from the investors鈥 perspective
- What鈥檚 hot in life sciences and where is the smart money being invested?
- Ways to gain exposure to the biotech boom: Stocks, funds, private equity, venture capital or else? Expert investor鈥 views on the best vehicles for biotech investment
- Funding the future of biotech: Key challenges and opportunities
Moderator: David Blake, Editor, BIOSHARES
Panellists:
Dr Jonathan Wang, Senior Managing Director, ORBIMED ASIA
Jeremy Curnock Cook, Managing Director, BIOSCIENCE MANAGERS
Scott Power, Director of Research, RBS MORGANS
Dr Joshua Funder, Partner, GBS VENTURE PARTNERS |
| 10:15 |
Biotech Company Spotlight Presentations
Julie Phillips, CEO, BIODIEM (ASX:BDM)
Dr John Holaday, Managing Director, CEO and CSO, QRXPHARMA (ASX:QRX)
Dr Brad Walsh, CEO, MINOMIC INTERNATIONAL
Dr Greg Collier, CEO, INVION (ASX:IVX)
Howard Digby, Executive Director, ECOQUEST (ASX:ECQ) |
| 11:00 |
Morning refreshments and networking with exhibitors |
| 11:30 |
The changing face of biotech investment
- Assessing the current state of venture capital and private equity investment into biotech
- Examining the role of institutional investors in the biotech space
- Attracting super funds to invest in biotech
- Managing risk at all stages: Exploring risk mitigation strategies for biotech investors
- Lessons learned from investing in biotech
Moderator: David Blake, Editor, BIOSHARES
Panellists:
Lawrence Gozlan, Chief Investment Officer and Founder, SCIENTIA CAPITAL
Michael Glenane, Executive Director, FAIRVIEW EQUITY PARTNERS
John Granger, Founder, HAWKESBURY PARTNERS
Graeme Colley, Director of Technical and Professional Standards, SELF MANAGED SUPER FUNDS PROFESSIONALS鈥 ASSOCIATION OF AUSTRALIA
Ron Laufer, Senior Managing Director, MEDIMMUNE VENTURES |
| 12:15 |
Biotech Company Spotlight Presentations
Dr Deborah Rathjen, CEO, BIONOMICS (ASX:BNO)
Dr Paul MacLeman, Chief Executive Officer, IDT AUSTRALIA (ASX:IDT)
Dr Malcolm McColl, CEO, VIRALYTICS (ASX:VLA)
Dr Michelle Miller, CEO, BIOTRON (ASX:BIT)
Charles Walker, Chief Executive Officer, ALCHEMIA (ASX:ACL) |
| 13:00 |
Lunch and networking with exhibitors |
|
VALUATION & RISK ASSESSMENT
|
| 14:00 |
Valuing biotech opportunities and optimising risk-return ratios
• Identifying investment opportunities and risk-return prospects across the development and patent lifecycle of a biotech company
• Putting a price on biotech:How to value patents,management track records and expected future revenue/royalty streams
• Ten key factors to keep in mind when investing into life science companies
• Small,mid or large-cap?De-risking your portfolio by diversifying your biotech holding
• Utilising the discovery investment scoreboard technology to pick the best stocks
Dr Michael A• Berry,ManagingDirector,DISCOVERY INVESTING |
|
PARTNERING STRATEGIES
|
| 14:20 |
PHARMA PANEL: Strategic partnering for long-term success
- Examining successful partnership models: How to achieve a win-win partnership
- Commercialising innovation: Impact of strategic alliances and JVs on cost / revenue models and success rate of drug development
- Partnerships key challenges and opportunities
Moderator: David Blake, Editor, BIOSHARES
Panellists:
Augustine Yee, Asia Pacific Head of Regional and Corporate Business Development and China Vice President of Business Development,ASTRAZENECA
Dr James Garner, Vice President & General Manager, Takeda Global Research & Development Centre Asia, TAKEDA
Dr Martin Judge, Director, Strategy and Sourcing, NOVO NORDISK A/S
Dr Brian Bloomquist, Senior Director, Global External Research and Development, ELI LILLY
Dr Raman Rao, Head External R&D, Asia Pacific, SANOFI PASTEUR |
| 15:00 |
Biotech Company Spotlight Presentations
Carl Stubbing, Chief Business Officer, BENITEC BIOPHARMA (ASX:BLT)
Dr Julian Chick, COO, ALLIED HEALTHCARE GROUP (ASX:AHG)
Dr Andrea Grant, CEO, LIVING CELL TECHNOLOGIES (ASX:LCT)
Mark Diamond, Managing Director & CEO, ANTISENSE THERAPEUTICS (ASX:ANP) |
| 15:35 |
Afternoon tea and networking with exhibitors |
|
R&D and TAX INCENTIVES
|
| 16:00 |
Maximising your after tax return on investment in Australia 鈥 strategies and opportunities
- Tax and financial structures for start-ups in order to leverage the R&D incentive and maximise Return on Investment
- Current 鈥渟tate of play鈥 of the R&D tax incentives and grants available
- Biotech start-up tax case study 鈥 tips and traps for first time and experienced applicants, including tax and R&D considerations
- Australian Manufacturing Incentive
Helen Fisher, Corporate & International Tax Partner, DELOITTE
Sergio Duchini, R&D & Government Incentives Partner, DELOITTE |
|
ANALYSTS鈥 VIEW
|
| 16:45 |
ANALYST ROUNDTABLE: Analysing the biotech boom
- Biotech drivers and performance in Australia and New Zealand
- What stocks are on the analysts鈥 watchlist and why?
Moderator: David Blake, Editor, BIOSHARES
Panellists:
Marc Sinatra, Equities Analyst, LODGE PARTNERS
Dr Graeme Wald, Investment Director, BIOSCIENCE MANAGERS
Scott Power, Director of Research, RBS MORGANS
Dr Matthijs Smith, Senior Analyst, CANACCORD GENUITY |
| 17:30 |
Networking Drinks Reception |
Conference Day Two 29 October 2013
| 08:30 |
Registration and morning coffee |
| 09:00 |
Conference chairman鈥檚 opening remarks and day one recap |
|
| Dr Fintan Walton, Founder and CEO, PHARMAVENTURES |
|
BIOTECH PERFORMANCE AND GROWTH OUTLOOK
|
| 09:15 |
Biotech financing and business models for future growth
• Key success factors and business models to monetise innovation
• Access to finance:Capital raising for early and late-stage biotechs
• Investment exit strategies anno 2013
Kellee Kim,ResearchAnalyst,ECOR1CAP |
| 09:35 |
BIOTECH BROKERS PANEL: Outlook for life science stocks
- Assessing the performance of life science stocks across key exchanges
- Spotlight on recent listings and upcoming IPOs
- Small-cap, mid-cap, large-cap: Where are the best opportunities?
Moderator: Dr Fintan Walton, Founder and CEO, PHARMAVENTURES
Panellists:
Joanna Hill, Client Services Manager, EL & C BAILLIEU STOCKBROKING
Steven Yatomi-Clarke, Director Corporate Finance, PATERSONS SECURITIES
Sam Street, Associate Director Corporate Finance, RBS MORGANS
James Posnett, Manager, Listing Business Development, ASX |
| 10:15 |
Biotech Company Spotlight Presentations
Geoffrey Kempler, Executive Chairman, PRANA BIOTECHNOLOGY (ASX:PBT)
Dr Tom McCarthy, Chief Executive Officer & Managing Director, SPINIFEX PHARMACEUTICALS
Roger McPherson, CFO, PATRYS (ASX:PAB)
Dr Geoff Cumming, CEO, ANTEO DIAGNOSTICS (ASX:ADO)
Dr Cliff Holloway, CEO, IMMUNE SYSTEM THERAPEUTICS |
| 11:00 |
Morning refreshments and networking with exhibitors |
| 11:30 |
Spotlight on Victoria鈥檚 biotechnology industry capabilities Representative, VICTORIAN GOVERNMENT |
|
PROTECTING YOUR IP RIGHTS
|
| 12:00 |
IP Due Diligence for capital raising and investment
- Potential threats to a biotech company鈥檚 IP rights
- Getting your IP house in order prior to raising capital
- Security around IP that investors should seek when investing into biotech
|
| 12:30 |
Biotech Company Spotlight Presentations
Simon Wilkinson, Director & CEO, INNATE IMMUNOTHERAPEUTICS
Nick Weston, Chairman & CEO, AGENIX (ASX: AGX)
Mike Thomas, CEO, ISONEA (ASX:ISN)
Marc Storms, Marketing Manager, FEI (NASDAQ:FEIC) |
| 13:05 |
Lunch and networking with exhibitors |
|
ASIA AND CHINA FOCUS SESSION
|
| 14:15 |
Asia鈥檚 growing role in biotech innovation and investment
• Examining Asia鈥檚 biotech landscape and key drivers for future growth
• Flows of biotech innovation and investment into and out of Asia
• Market outlook and opportunities for Australian-Asian partnerships
Dr Jason Mann,ManagingDirector,FENEX CAPITAL MANAGEMENT |
| 14:35 |
How to access investment out of China?
- What do investors in China look for when investing into biotech companies? What types of companies at what stage are most favoured?
- Pitch perfect: How can biotech companies best position themselves to attract capital and/or set up partnerships in China?
- Exploring biotech capital raising success stories and successful investor exits
- Accessing grants and funding and collaborating across borders
Moderator: Dr Fintan Walton, Founder and CEO, PHARMAVENTURES
Panellists:
Rob Scott, Director, CHINA BLUESKY VENTURES
Dr Benjamin Chen, Managing Partner, IGNATIUS TRANSACTION PARTNERS
David Cheng, Chief Investment Officer, COLAND HOLDINGS
Dr Jason Mann, Managing Director, FENEX CAPITAL MANAGEMENT |
| 15:05 |
Biotech Company Spotlight Presentations
Uwe Schlokat, CEO, SENTINEXT THERAPEUTICS
Mark Heffernan, Chief Executive Officer, NEXVET BIOPHARMA
Nick Ede, Executive Director, IMUGENE (ASX:IMU)
Dr Clement Leong, Chief Executive Officer,ASCEND BIOPHARMACEUTICALS |
| 15:40 |
Afternoon tea and networking with exhibitors |
|
THE FUTURE OF BIOTECH INVESTMENT
|
| 16:00 |
Creating value from spin-offs |
| |
- Role of universities to drive the next generation of biotech innovation
- Importance of university spin-offs to put research to commercial use
- How to create investor value from spin-offs: Success stories and lessons learned
Moderator: Dr Fintan Walton, Founder and CEO, PHARMAVENTURES
Panellists:
Dr Chris Nave, Chief Executive Officer, MEDICAL RESEARCH COMMERCIALISATION FUND
Dr John Kurek, Investment Manager, UNISEED VENTURES
Dr Mel Billingsley, President and CEO, THE LIFE SCIENCES GREENHOUSE OF CENTRAL PENNSYLVANIA
Ron Laufer, Senior Managing Director, MEDIMMUNE VENTURES |
| 16:30 |
Biotech Company Spotlight Presentations
Dr Richard Hopkins, CEO, PHYLOGICA (ASX: PYC)
Paul Wright, Chief Executive Officer, UNIVERSAL BIOSENSORS (ASX:UBI) |
| 16:50 |
Key challenges and investment opportunities for biotech in coming 10 years |
| |
- Key challenges and opportunities for biotech investment and innovation going forward
- Who will be funding early stage biotech to keep the momentum going?
- Key trends in the healthcare space and how these may affect biotech innovation and investment in the years to come
- Will biotech live up to its potential?
Moderator: Dr Fintan Walton, Founder and CEO, PHARMAVENTURES
Panellists:
Glenn Cross, Chief Operating Officer, AUSBIOTECH
Todd Davis, Managing Director, HEALTHCARE ROYALTY PARTNERS
Eric Shiozaki, Director, APPOSITE CAPITAL
Rhenu Bhuller, Global Vice President Pharmaceuticals/Biotechnology, FROST & SULLIVAN
Dr Stewart Washer, Chairman, ISONEA |
| 17:30 |
Chairman鈥檚 closing remarks and end of conference |
Profiles of previous delegates to Asia Biotech Invest 2013:
COMPANY TYPE
 |
Investors attending Asia Biotech Invest 2013 included:
8T8 Capital • AK Partners HK • AP Capital Group • Asia Pacific Investment Advisors • Avenue Capital Group • Ballingal Investment Advisors • Baring Private Equity Partners Asia • Baron Group Baron Capital • Bioscience Managers • BioVeda China Fund • BOCI-Prudential Asset Management • Business Succession Partners • Caitong International Asset Management • Capvest & Associates • CCB International Asset Management • Cedrus Investments HK • Celadon Capital Malaysia • Chepstow Capital Advisors • China BlueSky Ventures • CMS Asset Management HK • Creata Group • DAC Financial Management China • Decheng Capital • Deltec Capital • Discovery Investing • Ellis Brady Management HK • Etoile Asset Management • Fortune Time Capital Holding Group • Franklin Templeton Investments Asia • Global Mining Capital Corporation • Gottex Penjing Asset Management • Green Mountains Investments • Greenwoods Asset Management • Guangdong International Capital • GYK Holdings • Harmony Asset Management • Hong Kong Institute of Biotechnology • Infinity Group • JAG Investments • JPMorgan Asset Management Real Assets Asia • Kaiwu Capital • Khazanah Nasional Berhad • Leon CVM Capital Management Hong Kong • LGT Capital Partners Asia Pacific • Lilly Asia Ventures • Lim Global Investment & Research • Liomer Holdings • M H Carnegie & Co • Muse Capital • Nan Fung Group • Optivest Capital • OrbiMed Asia • Pacific West Asia Asset Management • PharmaVentures • Primavera Capital • Qiming Ventures • Quadria Capital • Qualita • Quam • RimAsia Capital Partners • Rock Spring Ventures • RRJ Management HK • Saba Capital • Sequoia Capital • Shaw Kwei & Partners • Sinovest Capital • STIC Investment • Stratagem Capital • Sumitomo Mitsui Asset Management HK • The Bank of East Asia • The Longreach Group • Tian An China Investments • Tripod Capital • Valiant Ocean Investment • Ventac Partners HK • Vivo Ventures • Wellcome Trust • Yuuwa Capital |
JOB FUNCTION
 |
INVESTORS - JOB FUNCTION
 |
鈥淔rom its first edition, Asia Biotech Invest is already the 鈥榤ust-go鈥 event for both biotech investors and fund-seekers in Asia鈥 Andrew Badrot, CMS Advisors
鈥淎s the world becomes increasingly Asia-centric, it is essential that our company develops links and contacts in the Biotech and Investment communities in Asia. The work of AusBiotech in proactively assisting in this through the Asia Biotech Invest summit enabled us to link in effectively and quickly. We鈥檒l be back.鈥 Sean Parsons, Ellume
鈥淲e were very pleasantly surprised by the number and calibre of the investors that attended the meeting. We had a number of very productive meetings and are pursuing two strong leads in our capital raising efforts directly as a result of the Asia Biotech Invest meeting.鈥 Dr Brad Walsh, Minomic International
Media Partners
To register, visit: http://www.AusBiotechInvest.com
call +852 2219 0111, email info@beaconevents.com, or fax to +852 2219 0112 |
中文
